Pharma's "Innovation" Label Is a Monopoly Extension Tool
The word "innovation" is doing a lot of legal heavy lifting in pharma — and almost none of the scientific kind. A new book argues the industry has systematically weaponized the term to justify patent evergreening that has nothing to do with therapeutic progress.
Explanation
Patent evergreening is the practice of filing new patents on minor tweaks to an existing drug — a new coating, a different dosage form, a slightly altered molecule — to reset the exclusivity clock and keep cheaper generics off the market. It's legal, widespread, and dressed up in the language of innovation.
Authors Tahir Amin and Rohit Malpani, writing in their book Pharma Monopoly, make a blunt distinction the industry prefers to blur: spending money on R&D is not the same as inventing something new. A company can pour billions into reformulating a pill that already exists and call it innovation. Regulators and courts often let that framing stand.
Why does this matter today? Because drug pricing debates almost always get derailed by the innovation argument. Whenever policymakers push for price controls or compulsory licensing, pharma responds that weakening patents kills the incentive to innovate. That argument only holds if the patents being protected actually cover genuine breakthroughs — which, the authors contend, is frequently not the case.
The practical consequence: patients and health systems pay monopoly prices for drugs that are, in therapeutic terms, essentially the same as older versions. The "new" product is protected; the affordable generic is blocked.
What to watch: whether drug patent reform proposals — currently active in the U.S., EU, and India — start drawing a harder legal line between genuine invention and incremental reformulation. If they do, pharma's favorite rhetorical shield gets a lot thinner.
Amin and Malpani's central intervention is definitional, not empirical — and that's both its strength and its limitation. By separating investment from invention, they target the core sleight of hand in pharma's public-affairs playbook: conflating R&D expenditure with patentable novelty. The distinction matters enormously in patent law, where "non-obviousness" and "novelty" are supposed to be high bars, but in practice secondary patents on minor modifications routinely clear them.
Evergreening is well-documented in the academic literature. Studies across the U.S., EU, and India have shown that a significant share of drug patents granted each year cover incremental changes — new salts, esters, polymorphs, delivery mechanisms — rather than new molecular entities with distinct clinical profiles. The I-MAK organization (co-founded by Amin) has previously published data showing that top-selling U.S. drugs hold an average of 140 patent applications each, with exclusivity periods stretching decades beyond the original compound patent.
The authors' framing is explicitly polemical — this is an opinion excerpt from an advocacy-oriented book, not a peer-reviewed study. That doesn't make the argument wrong, but it means the reader should expect prosecutorial selection of evidence rather than a balanced accounting of cases where secondary patents did protect genuine improvements.
The deeper structural question the excerpt raises but doesn't resolve: who decides what counts as "novel enough"? Patent offices, courts, and regulators apply different standards across jurisdictions, and pharma's legal teams are expert at forum-shopping. Reform proposals like the PREVAIL Act in the U.S. or India's Section 3(d) — which already bars secondary patents on known substances without demonstrated efficacy gains — represent attempts to codify exactly the distinction Amin and Malpani are arguing for.
Open question: if stricter novelty standards were uniformly applied, would the pipeline of genuinely new drugs shrink, or would capital simply stop flowing to evergreening and redirect toward first-in-class research? The evidence on that counterfactual remains contested.
Reality meter
Why this score?
Trust Layer Pharmaceutical companies routinely label incremental, non-novel modifications to existing drugs as 'innovation' in order to extend patent monopolies and block generic competition.
Pharmaceutical companies routinely label incremental, non-novel modifications to existing drugs as 'innovation' in order to extend patent monopolies and block generic competition.
- Authors Tahir Amin and Rohit Malpani directly state: 'Just because a company invests does not mean it has invented anything novel.'
- The piece frames the use of the word 'innovation' as a deliberate strategic weapon, not a neutral descriptor.
- The argument is drawn from a book titled 'Pharma Monopoly,' indicating a sustained, structured critique rather than a single op-ed claim.
- The source is an opinion excerpt from an advocacy book — no independent data, case studies, or quantitative evidence is quoted in the excerpt itself.
- At least one author (Tahir Amin) co-founded I-MAK, an organization explicitly campaigning against pharma patent practices, representing a clear conflict of interest that readers should weigh.
- The excerpt makes no engagement with counterarguments — e.g., cases where secondary patents did protect clinically meaningful improvements.
The core claim — that investment ≠ invention — is a logical and legally grounded distinction, but the source provides no data or case evidence in the excerpt to empirically substantiate how often this gap occurs.
Framing is deliberately polemical ('weaponizes'), which is appropriate for an opinion piece but inflates the rhetorical temperature beyond what the thin excerpt can support.
If the argument gains traction in ongoing patent reform debates across the U.S., EU, and India, the downstream effect on drug pricing and generic access could be substantial — but the excerpt alone does not demonstrate that traction.
- 1 source on file
- Avg trust 80/100
- Trust 80/100
Time horizon
Community read
Glossary
- Evergreening
- A pharmaceutical industry practice of making minor modifications to existing drugs (such as new formulations or delivery mechanisms) and obtaining new patents to extend market exclusivity and delay generic competition, rather than developing entirely new medicines.
- Secondary patents
- Patents granted on incremental improvements or modifications to an existing patented drug, such as new salts, esters, or delivery mechanisms, rather than on the original active compound itself.
- Non-obviousness
- A legal standard in patent law requiring that an invention must not be an obvious variation of existing knowledge to someone skilled in the field; it is one of the key criteria for determining whether something qualifies for patent protection.
- Polymorphs
- Different crystalline forms of the same chemical compound that have different physical properties; in pharmaceuticals, creating new polymorphs of existing drugs is a common evergreening tactic.
- Forum-shopping
- The practice of strategically choosing which court or jurisdiction to file a legal case in, typically to take advantage of more favorable laws or judicial interpretations in that location.
- Section 3(d)
- An Indian patent law provision that bars secondary patents on known substances unless they demonstrate significant new therapeutic efficacy, designed to prevent evergreening and encourage genuine pharmaceutical innovation.
What's your read?
Your read shapes future topic weighting.
Your vote feeds topic weights, community direction and future prioritisation. Open community direction
Sources
Optional Submit a prediction Optional: add your prediction on the core question if you like.
Prediction
Will at least one major jurisdiction (U.S., EU, or UK) pass legislation explicitly restricting secondary pharmaceutical patents on non-novel modifications by 2027?